Menu
Search
|

Menu

Close
X

INSYS Therapeutics Inc INSY.OQ (NASDAQ Stock Exchange Global Market)

7.83 USD
-0.46 (-5.55%)
As of Jul 20
chart
Previous Close 8.29
Open 8.31
Volume 173,381
3m Avg Volume 130,796
Today’s High 8.35
Today’s Low 7.67
52 Week High 14.00
52 Week Low 4.10
Shares Outstanding (mil) 72.70
Market Capitalization (mil) 644.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
24
FY17
141
FY16
242
FY15
330
EPS (USD)
FY18
-0.276
FY17
-3.049
FY16
0.101
FY15
0.765
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
3.37
5.73
Price to Book (MRQ)
vs sector
2.42
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-5.71
14.61
Return on Equity (TTM)
vs sector
-5.88
16.34

EXECUTIVE LEADERSHIP

Steven Meyer
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Saeed Motahari
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Andrew Long
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Venkat Goskonda
Senior Vice President - Research & Development, Since
Salary: --
Bonus: --
Steve Sherman
Senior Vice President - Regulatory Affairs, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10220 S 51st St Ste 2
PHOENIX   AZ   85044-5231

Phone: +1602.9102617

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

SPONSORED STORIES